

# Cystic Fibrosis: Market Research Report

<https://marketpublishers.com/r/C1D1590E5CFEN.html>

Date: December 2017

Pages: 252

Price: US\$ 5,450.00 (Single User License)

ID: C1D1590E5CFEN

## Abstracts

This report analyzes the worldwide markets for Cystic Fibrosis in US\$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2022. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 56 companies including many key and niche players such as -

Advanced Inhalation Therapies (AIT) Ltd.

AbbVie Inc.

Galapagos NV

Genentech, Inc.

Gilead Sciences, Inc.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

#### II. EXECUTIVE SUMMARY

##### 1. MARKET OVERVIEW

Cystic Fibrosis – A Prelude  
CF Disease Prevalence: A Brief Note

##### **Table 1.** Prevalence of Cystic Fibrosis across Select Countries

Treatment Modalities for Cystic Fibrosis  
CFTR Modulators: Key Drug Category  
Competitive Scenario

##### **Table 2.** Leading CF Drugs on the Market (2016): Percentage Share Breakdown by Sales (includes corresponding Graph/Chart)

Vertex: At the Forefront of Cystic Fibrosis Therapeutics

#### 2. RESEARCH IN CYSTIC FIBROSIS SPACE

Areas of Research & Development  
Gene Therapy – A Step Towards Cure  
Research Findings & Innovations  
Updated CF Diagnosis Guidelines to Aid in Diagnosis and Personalized Treatment  
Pipeline Drugs – An Overview  
Select Pipeline Drugs for Cystic Fibrosis Treatment by Development Stage, 2016  
Description of Select Pipeline Drugs  
Ataluren  
VX-661 + Ivacaftor  
Riociguat

##### **QBW251**

**CTP-656**

Cavosonstat (N91115)

**VX-440****QR-010**

pGM169/GL67A

Acebilustat

Resunab

Inhaled Mannitol

**VX-371**

Inhaled Levofloxacin (Quinsair)

AeroVanc (Vancomycin Inhalation Powder)

**3. DISEASE OVERVIEW**

Cystic Fibrosis – A Hereditary Disease

Mutation in CFTR Gene – A Major Cause of CF

(F508 – The Most Common Mutation that Affects CFTR Protein)

**Table 3.** Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)

Hereditary Risk of the Disease

Pathophysiology of the Disease

Symptoms of Cystic Fibrosis

Common Symptoms in Early Childhood

Common Symptoms in Grownups or Adults:

Complications Associated with Cystic Fibrosis

Sinus and Lung Illness

Pancreatic, Gastrointestinal, and Liver Disease

Endocrine Disorders

Infertility

Diagnosis of Cystic Fibrosis

Newborn Test  
Sweat Test  
The IRT Test  
Carrier Test  
Antenatal Test  
Other Common Tests  
Prenatal Diagnosis of Cystic Fibrosis  
Tests to Diagnose CF-Related Complications  
Cystic Fibrosis in Children

#### **4. CYSTIC FIBROSIS TREATMENT: AN OVERVIEW**

#### **5. CLINICAL STUDIES**

Vertex Pharmaceuticals Announces Positive Phase 3 Study Results of ORKAMBI  
ProQR Therapeutics Announces Positive Proof-of-Concept Study for QR-010  
Concert Pharmaceuticals Presents Positive Food Effect Results for CTP-656  
Vertex Pharmaceuticals Initiates Phase 2 Studies for VX-440 & VX-152  
Vertex Pharmaceuticals Provides Update on Phase 3 Study of VX-661 with ivacaftor  
Protalix BioTherapeutics Announces Start of Phase II Trial of AIR DNase (PRX-110)  
Nivalis Therapeutics Announces Completion of Enrollment for Phase 2 Study of N91115  
Alaxia SAS Announces Agreement and Grant from CFFT for ALX-009 Studies  
Polyphor Completes Successful Phase I Study of Inhaled POL6014  
AlgiPharma Receives Grant from CFFT for Phase 2 Trials of OligoG  
Health Canada Grants Clearance to ProMetic for its PBI-4050  
Cystic Fibrosis Canada Finances Laurent Pharmaceuticals' LAU-7b Phase 2 Trial  
Galapagos NV Begins Phase 2 Study of GLPG1837  
Pharmaxis Announces Positive Phase II Trial Results of Bronchitol  
PTC Therapeutics Completes Enrollment for second Phase 3 clinical trial of Translarna  
Anthera Pharmaceuticals Begins Phase 3 Study of Oral Liprotamase  
Parion Sciences Announces Expanded Enrollment Criteria for CLEAN-CF Trial  
Laurent Announces Positive Phase 1b Trial Results for LAU-7b  
Celtaxsys Announces Positive Phase 1 Clinical Trial Data of CTX-4430  
Corbus Pharmaceuticals Receives USFDA Clearance to Initiate Phase 2 Study of Resunab  
Savara Pharmaceuticals Unveils Positive Phase 2 Trial Results of AeroVanc  
KaloBios Reports Top-line Data from Phase 2 Study of KB001-A  
Galapagos NV Nominates GLPG2222 for Combination Therapy with GLPG1837  
Cystic Fibrosis Trust and NovaBiotics Partner for the Phase IIa Study of Lynovex

PTC Therapeutics Initiates Phase 3 Trial of Translarna/ataluren  
Kamada to Start Clinical Study of Alpha-1 Antitrypsin (AAT) for Cystic Fibrosis

## **6. PRODUCT LAUNCHES/APPROVALS**

EC Grants Orphan Drug Designation to Corbus Pharmaceuticals' Resunab  
FDA Approves Vertex's ORKAMBI for Extended Age Group  
Pharmaxis Announces Approval of Bronchitol in Russia  
FDA Grants Orphan Drug Status to Pulmatrix's CF Drug PUR1900  
ProQR Therapeutics Announces FDA Fast Track Designation for QR-010  
Alcresta Therapeutics Launches Relizorb Cartridge  
EC Grants Orphan Medicinal Product Designation to Arch Biopartners' AB569  
TGV-Inhalonix Receives Orphan Drug Designation for its Mul-1867  
RespirTech Launches Development of Remote Monitoring System for CF  
Vertex Pharmaceuticals Receives TGA Approval of ORKAMBI  
AlgiPharma's OligoG Receives Orphan Drug Designation by FDA  
Proteostasis Therapeutics Receives FDA Fast Track designation for PTI-428  
Proteostasis Therapeutics Expands CF Drug Pipeline  
Vertex Pharmaceuticals Receives Two EU Approvals for KALYDECO  
USPTO Issues Patent to OrPro Therapeutics' Theradux  
FDA Approves Vertex's ORKAMBI  
Advanced Inhalation Therapies Receives Orphan Medicinal Product Designation for AIT-CF from EMA  
FDA Approves New Age Group Indication for Vertex Pharmaceuticals' KALYDECO  
Sandoz Launches Tobramycin Inhalation Solution in the US  
FDA Approves sNDA for KALYDECO  
EC Grants Orphan Designation to Macrolide CF Drug by Synovo GmbH

## **7. RECENT INDUSTRY ACTIVITY**

Pharmaxis Enters into Research Collaboration with Woolcock Institute  
Horizon Pharma Acquires Raptor Pharmaceutical  
AstraZeneca to Sell Drug Commercialization Rights to Pfizer  
Vertex Pharmaceuticals and Moderna Therapeutics Enter into Research Collaboration  
Editas Medicine Enters into Agreement with CFFT for CRISPR/Cas9-based CF Drugs  
Galapagos and AbbVie Expand Agreement for CF Portfolio  
Raptor Pharmaceutical Acquires Quinsair from Tripex Pharmaceuticals  
Galapagos NV Enters into Licensing Agreement with the HUB Foundation  
Zambon SpA Acquires Nigaard Pharma

ManRos and Cyclacel Enter into Licensing Agreement for Seliciclib  
Vertex and Parion Sciences Collaborate to Develop Investigational CF Treatment  
Ruthigen and Pulmatrix Enter into Merger Agreement  
N30 Pharmaceuticals Changes Name to Nivalis Therapeutics  
Anthera Pharmaceuticals Acquires Sollpura/liprotamase from Eli Lilly  
OPKO Health Acquires Inspiromatic dry powder inhaler from Inspiro Medical  
CURx Pharmaceuticals Enters into Global License Agreement with Gilead Sciences

## **8. SELECT CLINICAL-STAGE PLAYERS**

Advanced Inhalation Therapies (AIT) Ltd (Israel)  
Alaxia SAS (France)  
AlgiPharma AS (Norway)  
Anthera Pharmaceuticals, Inc. (USA)  
Arch BioPartners (Canada)  
Celtaxsys, Inc. (USA)  
Concert Pharmaceuticals, Inc. (USA)  
Corbus Pharmaceuticals Holdings, Inc. (USA)  
CURx Pharmaceuticals (USA)  
Nivalis Therapeutics, Inc. (USA)  
NovaBiotics Ltd (UK)  
Parion Sciences, Inc. (USA)  
Pharmaxis Ltd (Australia)  
PTC Therapeutics, Inc. (USA)  
Pulmatrix, Inc. (USA)

## **9. FOCUS ON SELECT GLOBAL PLAYERS**

AbbVie Inc. (USA)  
Galapagos NV (Belgium)  
Genentech, Inc. (USA)  
Gilead Sciences, Inc. (USA)  
Novartis AG (Switzerland)  
Vertex Pharmaceuticals (USA)

## **10. GLOBAL MARKET PERSPECTIVE**

**Table 4.** World Recent Past, Current and Future Analysis for Cystic Fibrosis

Therapeutics by Geographic Region - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)

**Table 5.** World 7-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2016 and 2022 (includes corresponding Graph/Chart)

**Table 6.** World Recent Past, Current and Future Analysis for Cystic Fibrosis Therapeutics by Drug Type - Mucolytics, CFTR Modulators, Anti-Infectives, PERT, and Bronchodilators Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)

**Table 7.** World 7-Year Perspective for Cystic Fibrosis Therapeutics by Drug Type - Percentage Breakdown of Dollar Sales for Mucolytics, CFTR Modulators, Anti-Infectives, PERT, and Bronchodilators Markets for Years 2016 and 2022 (includes corresponding Graph/Chart)

### III. MARKET

#### 1. THE UNITED STATES

##### A. Market Analysis

Snapshots of Cystic Fibrosis (CF) Prevalence in the US

CFFT: NGO Dedicated to Cystic Fibrosis

List of Drugs (Companies) in the US Funded by CFFT for Cystic Fibrosis (2016)

Drug Pricing in Wake of Orkambi's High Price

Clinical Studies

Product Launches

Strategic Corporate Developments

Select Key Players

Clinical-Stage Players

##### B. Market Analytics

**Table 8.** US Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics Analyzed with Annual Sales Figures in US\$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)

## 2. CANADA

### A. Market Analysis

Clinical Studies

Product Launch

Arch BioPartners: Player Review

### B. Market Analytics

**Table 9.** Canadian Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics Analyzed with Annual Sales Figures in US\$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)

## 3. EUROPE

### A. Market Analysis

**Table 10.** Number of Cystic Fibrosis Patients in Europe by Country (2014) (includes corresponding Graph/Chart)

**Table 11.** Proportion of CF Patients in Europe (Adults Vs Children) by Country (2014) (includes corresponding Graph/Chart)

Clinical Studies

Product Launches

Strategic Corporate Developments

Select Key Players

### B. Market Analytics

**Table 12.** European Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics Analyzed with Annual Sales Figures in US\$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)

## 4. REST OF WORLD

### A. Market Analysis

Australia – High Out-of-Pocket Expenditure by CF Patients



Clinical Studies

Product Launch

Strategic Corporate Development

Select Key Players

B. Market Analytics

Table 13: Rest of World Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics Analyzed with Annual Sales Figures in US\$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)III-26IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 56 (including Divisions/Subsidiaries - 58)

The United States (30)

Canada (4)

Europe (20)

France (2)

Germany (2)

The United Kingdom (3)

Italy (2)

Rest of Europe (11)

Asia-Pacific (Excluding Japan) (1)

Middle East (3)

## I would like to order

Product name: Cystic Fibrosis: Market Research Report

Product link: <https://marketpublishers.com/r/C1D1590E5CFEN.html>

Price: US\$ 5,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1D1590E5CFEN.html>